Jinghua Weikang Capsule in the Treatment of Reflux Esophagitis
Status:
Not yet recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
Reflux esophagitis is a common clinical disease ; pPI or potassium competitive acid blocker (
P-CAB ) is the first choice for the treatment of reflux esophagitis. However, patients with
recurrent symptoms and severe esophagitis ( Los Angeles grade C and D ) after long-term use
of PPI or P-CAB usually need long-term maintenance treatment. Attention should be paid to the
possible adverse reactions of long-term acid suppression therapy and the interaction between
drugs. The main efficacy of Jinghua Weikang capsules is regulating qi and dispersing cold,
clearing heat and removing blood stasis. Applicable to cold and heat syndrome, qi stagnation
and blood stasis caused by epigastric distension, pain, belching, acid reflux, noisy, bitter
taste ; duodenal ulcer see the above syndrome. In the early stage, a series of studies were
carried out on Jinghua Weikang Capsule, which confirmed that Jinghua Weikang Capsule showed
the effect of acid inhibition and symptom relief in the treatment of reflux esophagitis, and
had a synergistic effect when combined with western medicine. However, Jinghua Weikang
Capsule still lacks sufficient evidence to support the reduction of the recurrence rate of
reflux esophagitis. Therefore, we carried out this experiment to explore the clinical
efficacy of Jinghua Weikang Capsule in the maintenance treatment of reflux esophagitis, so as
to reduce the recurrence rate of reflux esophagitis and relieve symptoms.
Phase:
Phase 4
Details
Lead Sponsor:
The First Affiliated Hospital of Dalian Medical University